Soleno Therapeutics, Inc.
SLNO
$76.70
-$0.08-0.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.56% | -24.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.24% | -25.90% | |||
| Operating Income | 27.24% | 25.90% | |||
| Income Before Tax | 21.81% | 26.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.81% | 26.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.81% | 26.93% | |||
| EBIT | 27.24% | 25.90% | |||
| EBITDA | 27.47% | 26.07% | |||
| EPS Basic | 25.63% | 30.34% | |||
| Normalized Basic EPS | 30.26% | 29.94% | |||
| EPS Diluted | 25.63% | 30.34% | |||
| Normalized Diluted EPS | 30.26% | 29.94% | |||
| Average Basic Shares Outstanding | 5.13% | 4.89% | |||
| Average Diluted Shares Outstanding | 5.13% | 4.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||